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Abstract
Antiretroviral therapy is currently only capable of controlling HIV replication rather than completely eradicating virus from
patients. This is due in part to the establishment of a latent virus reservoir in resting CD4+ T cells, which persists even in the
presence of HAART. It is thought that forced activation of latently infected cells could induce virus production, allowing
targeting of the cell by the immune response. A variety of molecules are able to stimulate HIV from latency. However no
tested purging strategy has proven capable of eliminating the infection completely or preventing viral rebound if therapy is
stopped. Hence novel latency activation approaches are required. Nanoparticles can offer several advantages over more
traditional drug delivery methods, including improved drug solubility, stability, and the ability to simultaneously target
multiple different molecules to particular cell or tissue types. Here we describe the development of a novel lipid
nanoparticle with the protein kinase C activator bryostatin-2 incorporated (LNP-Bry). These particles can target and activate
primary human CD4+ T-cells and stimulate latent virus production from human T-cell lines in vitro and from latently infected
cells in a humanized mouse model ex vivo. This activation was synergistically enhanced by the HDAC inhibitor sodium
butyrate. Furthermore, LNP-Bry can also be loaded with the protease inhibitor nelfinavir (LNP-Bry-Nel), producing a particle
capable of both activating latent virus and inhibiting viral spread. Taken together these data demonstrate the ability of
nanotechnological approaches to provide improved methods for activating latent HIV and provide key proof-of-principle
experiments showing how novel delivery systems may enhance future HIV therapy.
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Introduction
Highly active antiretroviral therapy (HAART) can powerfully
suppress HIV replication but does not clear virus from infected
individuals. Various reservoirs of replication-competent HIV have
been identified that may contribute to this persistence, the most
prominent and well-characterized of these being latently infected
CD4+ T-cells. Several attempts have been made to clear the latent
HIV reservoir but these have not been successful in eliminating all
latently infected cells or in preventing virus rebound upon
cessation of therapy [1,2,3,4]. Hence, complete eradication of
HIV from infected individuals will probably require further
improvements in latency activators and the development of a more
optimized virus purging strategy.
One focus of latency research is the identification of factors that
can activate HIV from latency and have the potential to be used in
a clinical setting. Such factors have included histone deacetylase
inhibitors, agonistic anti-CD3 antibodies, and cytokines such as
interleukin (IL)-2 and IL-7 [2,4,5,6,7,8]. A promising lead in this
context is the protein kinase C (PKC) activator bryostatin, which is
part of the marine macrolide class of molecules. Bryostatin has
been demonstrated to activate latent HIV at nanomolar
concentrations in vitro [9,10,11]. This molecule is believed to
induce expression of HIV by activating NFkB [12], which is
required for optimal transcription of viral mRNA from the HIV
long terminal repeat promoter (LTR). Although bryostatin-1 has
been tested in clinical trials for its anti-cancer properties
[13,14,15,16,17,18] there are no published studies using this class
of compounds in clinical HIV purging strategies. Bryostatin-2 was
used in our studies and has slightly different properties than the
parent compound bryostatin-1, although both can activate PKC at
nanomolar concentrations [13].
A second opportunity for improving latency activation is the
development of enhanced delivery vehicles for existing molecules.
Nanoparticle delivery systems possess several advantages over
more traditional drug delivery methods. For example, nanopar-
ticles can be used to modify drug solubility and bioavailability or to
allow multiple drugs to be incorporated into the same delivery
vehicle. Nanoparticles can also be targeted to particular cell or
tissue types, providing specificity that may not normally be a
characteristic of the incorporated drug. Numerous nanotechnolo-
gical systems have been approved for clinical use, including over
20 products for the delivery of various classes of drugs
[19,20,21,22]. Liposomes represent one type of nanoparticle that
has been a focus of basic research for over 40 years [23]. In the
past a major drawback in the clinical use of liposomes was their
rapid clearance due to uptake by mononuclear phagocytic cells.
Recent improvements in liposomal formulations have reduced this
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polyethylene glycol, thereby increasing the blood circulation time
[24]. These optimized liposomes have led to more clinically
applicable delivery systems as evidenced by the over 10 FDA
approved liposomal drug formulations, with several others in
clinical trials [25]. One example of this is doxorubicin incorpo-
rated into liposomes, known as Doxil. In 1995 this became the first
liposome based therapeutic to be approved by the FDA. Doxil was
initially used for treating HIV-related Kaposi’s sarcoma and was
later approved for ovarian and other types of cancers. Advantages
of Doxil over free drug properties included enhanced biodistribu-
tion and prolonged half life in blood circulation [26,27]. Our
particular study aimed to test the efficacy of a liposomal
formulation of the HIV latency activator bryostatin-2 and to test
whether this nanoparticle delivery platform can enhance the
ability to activate latent HIV.
Our current work is a proof-of-concept study demonstrating
that HIV latency activators can be packaged into nanoparticles,
either alone or in conjunction with an antiretroviral drug.
Bryostatin-2 loaded lipid nanoparticles (LNP-Bry) produced in
this way have enhanced activity compared with drug alone, and
can be further modified by adding targeting antibodies to make
them more selective for CD4+ T cells. This is the first
demonstration of the use of nanotechnology in HIV latency
activation and may provide a direction for more effective therapy
in future purging strategies.
Results and Discussion
LNP characterization and uptake in various cell types
It is becoming increasingly evident that HAART will not clear
HIV infection from the body; thus patients must stay on therapy
for the remainder of their lives. These therapies are associated with
several toxicities; therefore, the field has begun to explore ways to
purge residual viral reservoirs. One such approach involves
activation of latent reservoirs, in the context of HAART, with
the intent that the immune system will destroy the cells induced to
produce virus. Our aim was to develop a lipid nanoparticle (LNP)
delivery system that activates latent HIV and may have potential
for purging viral reservoirs. Historically, nanoparticles have
received particular attention in the area of cancer therapy; more
recently, nanoparticle delivery systems have also been used in HIV
antiretroviral research [28,29,30,31,32,33]. However, these studies
did not investigate the potential use of nanoparticles in the context
of HIV latency.
Bryostatin-2 was chosen for incorporation into the LNP due to
the low effective dosage for latent HIV activation (1–10 nM) as
well as the fact that this class of compounds have been widely used
in clinical trials exploring its anti-cancer properties
[13,14,15,16,17,18]; therefore bryostatin preparations could
possibly be more rapidly advanced to clinical trial for use in
HIV therapy. Bryostatin-2 incorporation was efficient due to its
small size (MW=863 daltons) and hydrophobic nature, which
allows it to be readily incorporated into the membrane of the LNP,
forming nanoparticles with an average size of 219 nm (Fig. 1A).
Further characterization showed efficient LNP uptake in various
cell types (Fig. 1B–D). The punctate dots observed in HeLa cells
and primary macrophages represent a classical sign of particles
localized in cellular compartments such as caveolea pits or early
endosomes. The diffuse layer of nanoparticles present in all three
tested cell types more likely represents a fusion event where LNP
are dispersing into the cellular membranes. LNP uptake in CEM
T-cells was found to be efficient, and proved to be dose,
temperature, and time dependent (Fig. 1E–F). The lipid
nanoparticles were non-toxic in all cell types tested including
peripheral blood mononuclear cells (PBMCs). These data
demonstrate the ability of our LNP delivery system to be efficiently
taken up into various cell types providing a platform in which we
can effectively deliver our cargo of interest, including the HIV
latency activator bryostatin-2 and the protease inhibitor nelfinavir.
Effects of LNP-Bry on uninfected primary CD4+ T cells
and latently infected cells
To determine whether bryostatin-2 loaded nanoparticles (LNP-
Bry) are capable of stimulating HIV from latency, we first utilized
the J-Lat cell line model, which expresses GFP upon activation of
latent HIV [34]. LNP-Bry were more effective than drug alone at
activating latent HIV at all doses tested (Fig. 2A–C). This may be
due to the increased drug solubility by the lipid nanoparticle or
increased local concentration of the drug near the cellular
membrane. Indeed, our uptake data indicate that LNP typically
associate with the membranes in T-cells and this interaction may
be responsible for the increased drug effects observed in our
system. It is interesting to note that the site of action for bryostatin-
2 is protein kinase C on the intracellular membrane, so it is
possible that the LNP-Bry provides a more efficient means of
delivering drug to this target. This is the first empirical evidence
that incorporation of bryostatin-2 into nanoparticles may provide
advantages over using drug alone. Consistent with the data
presented here, previous studies of other LNP-drug preparations
have also documented increased drug uptake in cells exposed to
lipid-drug formulations compared with drug alone [30,35].
Previous reports have described a synergistic HIV stimulatory
effect between HDAC inhibitors and PKC activators such as
prostratin [36] and bryostatin [10]. We found that the combina-
tion of LNP-Bry and the HDAC inhibitor sodium butyrate have a
far superior effect than either latency activator alone (Fig. 2D,E). It
is important to note that other HDAC inhibitors such as SAHA or
VPA have also been shown to synergize with PKC activators;
therefore these may also prove to be effective in combination with
nanoparticle delivery of PKC activators [36]. Finally, since any
purging strategy would probably necessitate effective stimulation
in primary CD4+ T-cells, we tested the ability of LNP-Bry to
induce the early activation marker CD69 (Fig. 2F–H). Similar to
our previous data, LNP-Bry was more effective at inducing CD69
expression compared with bryostatin-2 alone. Again, this demon-
strates the advantage of using this LNP system for the delivery of
bryostatin-2.
In order to test the ability of LNP-Bry to activate latent virus in
a primary cell model we utilized the SCID-hu (Thy/Liv) mouse
model for HIV latency [7,37,38,39,40,41,42]. Briefly, this model
involves transplantation of human fetal liver (as a source of stem
cells) and human fetal thymus under the kidney capsule of
immunodeficient mice. We have previously reported a high
proportion of latently infected mature human thymocytes in this
model [39]. The CD4/CD8 expression profile of mock and
infected implants at 4 weeks post-infection was consistent with our
previous data using this model, where CD4+CD8+ (double-
positive) cells are preferentially depleted by HIV (Fig. 2I). Mature
CD4 single-positive cells were then isolated and stimulated for 2
days in the presence of 1 mM raltegravir to prevent additional
virus infection during activation. Anti-CD3/anti-CD28 beads
served as a costimulation positive control. LNP-Bry and
bryostatin-2 were each capable of stimulating latent virus as
assessed by intracellular Gag protein expression (Fig. 2J). Culture
supernatants were also assayed for HIV p24 Gag protein using
ELISA, and activation from latency by LNP-Bry was again
evident. Taken together these data provide a proof–of-concept
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activation of latent HIV.
Incorporation of both a protease inhibitor and latency
activator into the same nanoparticle
One major potential benefit to the use of nanoparticles is the
ability to incorporate multiple classes of drugs into the same
delivery vehicle. Any HIV purging strategy would be performed in
the presence of HAART, but it would be useful to incorporate an
antiretroviral drug such as a protease inhibitor into the same
particle that is used to activate latent virus to directly introduce
higher levels of drug to the cells. Conceptually, this is similar to the
idea of HAART intensification during reservoir purging, and it
represents a safety feature whereby any virus induced by the
nanoparticles to express would produce viral epitopes, but would
be inactivated as it exits the host cell. This would allow subsequent
targeting by the immune response in the absence of increased
production of viable virus. This strategy may be particularly
important if particles are developed to enter anatomical sites that
are not easily penetrated by some antiretroviral drugs (such as the
brain). To this end, we incorporated the protease inhibitor
nelfinavir into our nanoparticles along with bryostatin-2 (LNP-
Bry-Nel). This particle can effectively inhibit virus spread in a
culture of CEM cells (Fig. 3A). The same particles were also able
to stimulate latent HIV expression in J-Lat 10.6 cells (Fig. 3B).
Hence, the LNP-Bry-Nel can effectively stimulate latent virus and
also inhibit virus spread, which further exemplifies the potential
benefits of using nanoparticles in HIV purging strategies.
Targeting of LNP to primary CD4+ cells and delivery of
bryostatin-2
Optimal therapeutics utilize the lowest possible effective dose while
minimizing off-target effects. Nanoparticles can be modified to
selectively target certain cells and thus optimize this balance of drug
delivery to the target site versus non-targeted sites. In particular,
liposomesoffer a biodegradable vehiclewhichiscapableof carrying a
variety of substances to targeted sites [23] achieved either through
passive or active targeting [19]. These targeting strategies may help
prevent toxicity due to generalized immune activation during efforts
to purge latent HIV. Therefore, we explored the possibility of adding
a level of selectivity to latency activators that might reduce bystander
cellactivation. The mostoptimal HIV purging strategy would involve
Figure 2. Effects of LNP-Bry on latent virus expression and induction of CD69. (A) Representative flow cytometry plots of GFP expressing J-
Lat 10.6 cells incubated with 10 nM bryostatin-2 or brostain-2 loaded LNP (LNP-Bry). (B) Percentage GFP+ cells was measured after incubation of LNP-
Bry or bryostatin-2 with J-Lat 8.4 cells for 16 hr. (C) Percentage GFP+ cells was measured after incubation of LNP-Bry or bryostatin with J-Lat 10.6 cell
lines for 16 hr. (D) Representative flow cytometry plots displaying the synergistic effect of 2 mM sodium butyrate (NaBut) in conjunction with LNP-Bry
in J-Lat 8.4 cells. (E) J-Lat 8.4 cells were incubated with a fixed dose of NaBut (2 mM) and increasing dose of bryostatin-2 or LNP-Bry. (F)
Representative flow cytometry plots displaying CD69 induction in primary resting CD4+ cells after incubation with LNP-Bry or bryostatin-2 for 16 hr.
(G) Percentage CD69+ cells as detected by flow cytometric analysis. (H) Fold increase in CD69 mean fluorescence intensity was measured after
incubation with increasing amounts of LNP-Bry or bryostatin-2 in primary CD4+ cells. (I) Flow cytometry plots displaying the CD4+/CD8+ cell profiles
from mock or NL4-3 infected SCID-hu (Thy/Liv) implants. (J) In the presence of 1 mM raltegravir, CD4 single-positive thymocytes were stimulated ex-
vivo with anti-CD3/CD28 beads, 10 nM bryostatin-2 or 10 nM LNP-Bry for 48 hr and assayed for intracellular Gag protein by flow cytometry. Error bars
indicate the standard deviation of triplicate data points and are representative of at least 2 experiments. * p,0.01 as compared with media only
(infected non-stimulated cultures) or LNP-con (non-drug loaded nanoparticles) in a paired t-test.
doi:10.1371/journal.pone.0018270.g002
Figure 1. Lipid nanoparticle (LNP) characterization and uptake in various cell types. (A) LNP were synthesized and characterized for their
size by dynamic light scattering. (B) The membrane stain wheat germ agglutinin (WGA) visualized in blue was used with fluorescent microscopy in
order to visualize the uptake of LNP-FITC (green) after a 16 hr incubation with HeLa cells. (C) WGA visualized in red was used to observe LNP-FITC
(green) uptake in primary macrophages. (D) CEM cells were visualized by phase contrast images with LNP (green) using fluorescent microscopy. (E)
LNP uptake in CEM cells was dose and energy dependent as detected by fold increase in FITC mean fluorescent intensity (MFI) using flow cytometry.
(F) LNP uptake in CEM cells also increased over time as detected by flow cytometry.
doi:10.1371/journal.pone.0018270.g001
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unachievable because there is no known distinguishing cell surface
marker for a latently infected cell [42]. However, it may still be
possible to activate only the subset of cells that may harbor the latent
infection and in doing so minimize cellular activation of all non-
targeted cells. Therefore for this proof-of-concept study we chose
CD4 as our target receptor for possible latently infected cells.
Targeted particles (LNP-CD4) did indeed target CD4+ cells in a
PBMC culture (Fig. 4A–D) when compared with isotype control
antibody coated particles (LNP-Iso). As expected LNP-Iso (non-
targeting) showed no preference for activating CD4+ or CD8+ T-
cells. In sharp contrast, when introduced into a mixed peripheral
blood cell culture LNP-CD4 preferentially induced CD69 expression
on CD4+ cells with minimal activation of CD8+ cells (Fig. 4E,F).
LNP-CD4 was also capable of activating latent HIV in J-Lat 8.4 cells
and primary thymocytes (Fig. 4G,H). These data demonstrate the
ability of nanoparticles to target and activate latent HIV in CD4+
cells while minimizing cellular activation of non-targeted cells. It is
important to note that when constructing the most optimal in vivo
purging strategy, multiple types of nanoparticles that target different
cells or tissue types could be used in combination. For example, while
CD4 targeting nanoparticles may be useful in systemic T-cell
targeting, unmodified liposomes have been documented to target
lymphoid tissue due to their size and drainage into lymphatic vessels
[43,44,45]. This type of combinatorial approach along with the idea
that both latency activators and protease inhibitors will be delivered
by the same vehicle may be used to enhance HIV latency purging
strategies in vivo.
Summary
In summary, our data illustrate the potential use of nanotech-
nology in HIV purging strategies. These data have provided a
proof-of-concept study for the use of nanodelivery systems in HIV
latency research. Taken together this study demonstrates several
advantages that targeted drug loaded nanoparticles can provide in
developing optimized strategies for HIV latency activation and will
provide a foundation for future novel HIV purging strategies.
Materials and Methods
Lipid nanoparticle formation and characterization
All lipids were purchased from Avanti Polar Lipids. Liposomes
were made by thin film evaporation methods described previously
[46]. PC, PE, PS lipids were used at a 40:40:20 molar ratio. 2%
FITC-PE was incorporated for fluorescently labeled lipids.
Bryostatin-2 was purchased from LC Laboratories. The particles
were purified from any free drug by PD 10 column (GE
Healthcare) separation. LNP were then characterized for size
using dynamic light scattering (Brookhaven Zeta Sizer Instru-
ment). Immunoliposomes with biotinylated-PE lipid (0.1% incor-
porated) were engineered according to previous protocols [47].
Biotinylated LNP were coated with NeutrAvidin (NA) (Pierce) and
purified from free protein using MW100 filters (Millipore). NA-
coated LNP were then incubated with either anti-CD4 Ab or
Isotype control Ab (1% w/w).
Cellular uptake of LNP
HeLa cells [48] were cultured in Dulbecco’s Modified Eagle
Medium + penicillin/streptomycin (PS) + 10% fetal bovine serum
(FBS). CD14+ monocytes were isolated using anti-CD14 magnetic
beads (Miltenyi) and cultured for 1 week in macrophage media
(Iscove’s Modified Dulbecco’s Medium + PS + 10% FBS + 5%
human AB serum) containing 10 ng/ml M-CSF (macrophage
colony stimulating factor). CEM cells [49] were cultured in RPMI
+ PS +10% FBS. Fluorescent microscopy images were taken using
a Zeiss observer Z1 microscope. Flow cytometry analysis of LNP
uptake in CEM cells was done by measuring fold increase in FL1
mean fluorescence intensity (MFI) using a flow cytometer (Beck-
man Coulter FC 500).
Activation of latent HIV and primary CD4+ cells
J-Lat clone 8.4, clone 10.6 or peripheral blood mononuclear
cells from healthy donors were incubated in RPMI + PS +10%
FBS. Primary thymocytes were cultured in RPMI + PS +10%
human AB serum. Flow cytometry analysis was performed on a
Figure 3. Simultaneous incorporation of the protease inhibitor nelfinavir (Nel) and bryostatin-2 (Bry) into the lipid nanoparticles
(LNP-Bry-Nel) can both activate latent virus expression and inhibit viral spread. (A) CEM cells were infected with HIVNL4-3 and the cells
were incubated for 3 days in the presence of various drug combinations including LNP-Bry-Nel. Viral p24 protein in the culture supernatant was
measured by ELISA. (B) LNP-Bry-Nel was further tested for its ability to activate latent virus in J-Lat 10.6 cells as measured by induction of GFP
expression. Error bars indicate the standard deviation of triplicate data points and are representative of at least 2 experiments. Media represents
untreated infected cultures and LNP-con represents non-drug loaded nanoparticles.
doi:10.1371/journal.pone.0018270.g003
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HIV in a primary cell model, SCID-hu (Thy/Liv) implants were
infected with 10 ng NL4-3 and the virus was allowed to spread for
4 weeks before tissue harvesting as described previously
[37,38,39]. Single positive CD4 cells were isolated by negative
selection using the CD4 negative isolation kit II (Miltenyi Biotec).
KC57-RD1 antibody was purchased from Beckman Coulter and
all other antibodies (CD69-PE-Cy7, CD4-PE, and CD8-APC)
were purchased from BD Biosciences.
NL4-3 spreading assay
Nelfinavir was incorporated into LNP in the same manner as
bryostatin-2 (dissolved in the organic phase of lipids) and separated
from free drug by PD10 columns. CEM cells were infected in bulk
(600,000 cells in 200 ul volume) with 5 ng/ml NL4-3 in the
presence of 10 mg/ml polybrene for 2 hr. Cells were washed and
plated in the presence of each indicated condition at a
concentration of 50,000 cells/well (1 ml total) in a 24-well plate.
Culture supernatant was collected at 3 days post-infection for p24
protein analysis by ELISA.
Ethics Statement
No human subjects were used in this study. Tissues from
anonymous sources are not considered human subjects, and are thus
not subject to Institutional Review Board review. Peripheral blood
was obtained through the UCLA Blood Bank in an anonymous
fashion. Similarly, fetal tissues were obtained in an anonymous
fashion from Advanced Bioscience Resources, Alameda, CA.
Figure 4. Targeting LNP to primary CD4+ cells and activation of latent virus expression. (A) Schematic representation showing
construction of the LNP-CD4 (anti-CD4 coated nanoparticles) and LNP-Iso (isotype control antibody coated nanoparticles) with bryostatin-2
incorporation. (B) Fluorescent microscopy image displaying the targeting of LNP-CD4 (green) to CD4+ cells (red) while minimizing cellular association
with CD8+ cells (violet) in the same culture of total peripheral blood mononuclear cells (PBMCs) after a 30 min exposure. (C) Fluorescent microscopy
image displaying the lack of targeting by LNP-Iso (green) to CD4+ cells (red) or CD8+ cells (violet). (D) Quantification of LNP-CD4 uptake in PBMCs
using flow cytometry (% cells CD4+ with increase in FITC-LNP uptake) after a 30 min exposure. (E) Representative flow cytometry plots of CD4+ and
CD8+ cells analyzed for the induction of the early activation marker CD69 after incubation with CD4 targeting nanoparticles for 16 hr. (F) Bar graphs
illustrating the fold increase in CD69 MFI in CD4+ and CD8+ cells after incubation with LNP-CD4 Bry. (G) LNP-CD4 Bry was further tested for its ability
to stimulate latent virus expression in J-Lat 8.4 cells. (H) Ex vivo CD4 single-positive thymocytes isolated from infected SCID-hu (Thy/Liv) implants were
incubated with LNP-CD4 Bry and viral p24 protein present in the culture supernatants was analyzed after 48 hr. Error bars indicate the standard
deviation of triplicate data points and are representative of at least 2 experiments. * p,0.01 in a paired t-test as indicted in (F) and as compared with
media only or LNP-con in (G) and (H).
doi:10.1371/journal.pone.0018270.g004
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recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the UCLA Animal Research Commit-
tee (approval #1996-058-43). All surgery was performed under
ketamine/xylazine anesthesia, and all efforts were made to
minimize suffering. For all survival surgeries carprofen analgesic
was also employed.
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